229 related articles for article (PubMed ID: 17986232)
1. Promyelocytic leukemia-nuclear body formation is an early event leading to retinoic acid-induced differentiation of neuroblastoma cells.
Delaune A; Corbière C; Benjelloun FD; Legrand E; Vannier JP; Ripoll C; Vasse M
J Neurochem; 2008 Jan; 104(1):89-99. PubMed ID: 17986232
[TBL] [Abstract][Full Text] [Related]
2. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
[TBL] [Abstract][Full Text] [Related]
3. Restoration of promyelocytic leukemia protein-nuclear bodies in neuroblastoma cells enhances retinoic acid responsiveness.
Yu JH; Nakajima A; Nakajima H; Diller LR; Bloch KD; Bloch DB
Cancer Res; 2004 Feb; 64(3):928-33. PubMed ID: 14871822
[TBL] [Abstract][Full Text] [Related]
4. Expression of promyelocytic leukemia protein increases during the differentiation of human neuroblastoma cells.
Yu E; Choi EK; Kim CJ
Virchows Arch; 2003 Mar; 442(3):278-83. PubMed ID: 12647219
[TBL] [Abstract][Full Text] [Related]
5. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA.
Bøe SO; Haave M; Jul-Larsen A; Grudic A; Bjerkvig R; Lønning PE
J Cell Sci; 2006 Aug; 119(Pt 16):3284-95. PubMed ID: 16868026
[TBL] [Abstract][Full Text] [Related]
6. A role for PML and the nuclear body in genomic stability.
Zhong S; Hu P; Ye TZ; Stan R; Ellis NA; Pandolfi PP
Oncogene; 1999 Dec; 18(56):7941-7. PubMed ID: 10637504
[TBL] [Abstract][Full Text] [Related]
7. β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.
Satow R; Shitashige M; Jigami T; Fukami K; Honda K; Kitabayashi I; Yamada T
Gastroenterology; 2012 Mar; 142(3):572-81. PubMed ID: 22155184
[TBL] [Abstract][Full Text] [Related]
8. The mechanisms of PML-nuclear body formation.
Shen TH; Lin HK; Scaglioni PP; Yung TM; Pandolfi PP
Mol Cell; 2006 Nov; 24(3):331-9. PubMed ID: 17081985
[TBL] [Abstract][Full Text] [Related]
9. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
[TBL] [Abstract][Full Text] [Related]
10. Role and fate of PML nuclear bodies in response to interferon and viral infections.
Regad T; Chelbi-Alix MK
Oncogene; 2001 Oct; 20(49):7274-86. PubMed ID: 11704856
[TBL] [Abstract][Full Text] [Related]
11. Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination.
Yeung PL; Denissova NG; Nasello C; Hakhverdyan Z; Chen JD; Brenneman MA
J Cell Biochem; 2012 May; 113(5):1787-99. PubMed ID: 22213200
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells.
Komura N; Asakawa M; Umezawa K; Segawa K
Exp Cell Res; 2007 Aug; 313(13):2753-65. PubMed ID: 17585903
[TBL] [Abstract][Full Text] [Related]
13. Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover.
Lim JH; Liu Y; Reineke E; Kao HY
J Biol Chem; 2011 Dec; 286(52):44403-11. PubMed ID: 22033920
[TBL] [Abstract][Full Text] [Related]
14. c-Myb associates with PML in nuclear bodies in hematopoietic cells.
Dahle Ø; Bakke O; Gabrielsen OS
Exp Cell Res; 2004 Jul; 297(1):118-26. PubMed ID: 15194430
[TBL] [Abstract][Full Text] [Related]
15. Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells.
Grignani F; Testa U; Fagioli M; Barberi T; Masciulli R; Mariani G; Peschle C; Pelicci PG
Cancer Res; 1995 Jan; 55(2):440-3. PubMed ID: 7529139
[TBL] [Abstract][Full Text] [Related]
16. PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3.
Testa U; Grignani F; Barberi T; Fagioli M; Masciulli R; Ferrucci PF; Seripa D; Camagna A; Alcalay M; Pelicci PG
Cancer Res; 1994 Aug; 54(16):4508-15. PubMed ID: 7519122
[TBL] [Abstract][Full Text] [Related]
17. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
18. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
[TBL] [Abstract][Full Text] [Related]
19. The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells.
Rousselot P; Hardas B; Patel A; Guidez F; Gäken J; Castaigne S; Dejean A; de Thé H; Degos L; Farzaneh F
Oncogene; 1994 Feb; 9(2):545-51. PubMed ID: 8290265
[TBL] [Abstract][Full Text] [Related]
20. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
